Testing for undetectable MRD is crucial for guiding time-limited venetoclax regimens but not continuous BTK inhibitor therapy. Continuous covalent BTK inhibitors rarely clear MRD despite delivering six to nine years of progression-free survival, making routine MRD assays pointless during ongoing monotherapy.
Stopping BTK inhibitor monotherapy early is typically discouraged, but patients with mutated IGHV can experience prolonged remissions after fixed-duration treatment. In a French study evaluating stopping acalabrutinib after one year, relapses predominantly clustered in unmutated IGHV cases, whereas mutated patients maintained durable disease control.
Standard FISH panels only identify 17p deletions and miss sequence-level TP53 mutations that carry similar poor prognoses. Clinicians must specifically order next-generation sequencing alongside stimulated karyotyping, because unstimulated CLL cultures fail to proliferate and can produce false-normal karyotypes.
Data from the frontline AMPLIFY trial revealed that adding obinutuzumab to an acalabrutinib and venetoclax doublet doubled grade 3 or higher infections from 10-12% to 24%. While the triplet drove higher undetectable MRD rates, the heightened risk of neutropenia and severe infections argues against its use in older, comorbid patients.
Initiating acalabrutinib and venetoclax upfront while delaying obinutuzumab effectively debulks tumor load before antibody exposure. This delayed-layering strategy significantly cuts infusion reactions, myelosuppression, and severe infection risk while preserving the deep responses necessary for complex or autoimmune manifestations.
In relapsed CLL, venetoclax-rituximab yields a median progression-free survival of under 40 months following covalent BTK inhibitor failure, compared to 54 months in historical chemoimmunotherapy trials. Intensifying therapy with a pirtobrutinib triplet (PVR) cuts progression risk by nearly half in this aggressive post-covalent BTKI population.
Although BTK degraders show exceptional activity in heavily pretreated CLL, using them as continuous frontline monotherapy raises serious sequencing concerns. Early mechanistic data reveal the A428D mutation can emerge, which confers broad cross-resistance to covalent, non-covalent, and degradation-based BTK-targeting therapies.
